Knee osteoarthritis (OA) is a common painful joint condition with high unmet need, often treated with intra-articular (IA) agents.

Lorecivivint (LOR) is an IA small molecule cdc2-Like Kinase (CLK)/Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase (DYRK) inhibitor in development as a potential OA treatment.

This study evaluated if injection of LOR in close time proximity prior to or following IA corticosteroid (triamcinolone) would impact safety or pharmacokinetics of either agent in healthy volunteers.

These results suggest that IA administration of LOR and triamcinolone in close proximity (7 days apart) is unlikely to pose a safety concern.